Rationale and design of the European Polyp Surveillance (EPoS) trials Journal Article


Authors: Jover, R.; Bretthauer, M.; Dekker, E.; Holme, O.; Kaminski, M. F.; Løberg, M.; Zauber, A. G.; Hernán, M. A.; Lansdorp-Vogelaar, I.; Sunde, A.; McFadden, E.; Castells, A.; Regula, J.; Quintero, E.; Pellisé, M.; Senore, C.; Kalager, M.; Dinis-Ribeiro, M.; Emilsson, L.; Ransohoff, D. F.; Hoff, G.; Adami, H. O.
Article Title: Rationale and design of the European Polyp Surveillance (EPoS) trials
Abstract: Background: Current guidelines recommend surveillance colonoscopies after polyp removal depending on the number and characteristics of polyps, but there is a lack of evidence supporting the recommendations. This report outlines the rationale and design of two randomized trials and one observational study investigating evidence-based surveillance strategies following polyp removal. Study design and endpoints: The EPoS studies started to recruit patients in April 2015. EPoS study I randomizes 13 746 patients with low-risk adenomas (1-2 tubular adenomas size <10mm, low-grade dysplasia) to surveillance after 5 and 10 years, or 10 years only. EPoS study II randomizes 13704 patients with high-risk adenomas (3-10 adenomas or adenoma >= 10mm in diameter, or adenoma with high-grade dysplasia, or >25% villous features) to surveillance after 3, 5, and 10 years, or 5 and 10 years only. EPoS study III offers surveillance after 5 and 10 years to patients with serrated polyps >= 10mm in diameter at any location, or serrated polyps >= 5mm in diameter proximal to the splenic flexure. All polyps are removed before patients enter the trials. The primary end point is colorectal cancer incidence after 10 years. We assume a colorectal cancer risk of 1% for patients in EPoS I, and 2% for patients in EPoS II. Using a noninferiority hypothesis with an equivalence interval of 0.5% for EPoS I and 0.7% for EPoS II, the trials are 90% powered to uncover differences larger than the equivalence intervals. For EPoS III, no power analyses have been performed. Conclusions: The present trials aim to develop evidence-based strategies for polyp surveillance, thereby maximizing effectiveness and minimizing resources.
Keywords: risk; adenoma; randomization; polypectomy; sigmoidoscopy; colorectal-cancer; society; removal; neoplasia; colonoscopy surveillance
Journal Title: Endoscopy
Volume: 48
Issue: 6
ISSN: 0013-726X
Publisher: Georg Thieme Verlag Kg  
Date Published: 2016-06-01
Start Page: 571
End Page: 578
Language: English
ACCESSION: WOS:000377042500012
DOI: 10.1055/s-0042-104116
PROVIDER: wos
PUBMED: 27042931
PMCID: PMC5412707
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ann G Zauber
    315 Zauber